<DOC>
	<DOCNO>NCT00171639</DOCNO>
	<brief_summary>This study conduct evaluate effect investigational drug bone loss men prostate cancer receive Androgen Deprivation Therapy ( ADT ) . In order participate , male patient 18 year old must veterans participate Veterans Administration Medical Centers receive ADT prostate cancer establish osteoporosis .</brief_summary>
	<brief_title>The Use Zoledronic Acid Men Androgen Deprivation Therapy Prostate Cancer With Preexisting Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Signed informed consent Age &gt; 18 year Histologically confirm diagnosis carcinoma prostate Stage M0 : Patients start ADT must stage M0 [ PSA &lt; 10 ( bone scan need ) negative bone scan ( regardless PSA ) ] . Patients already ADT must M0 initiation ADT maintain stable , low PSA ( &lt; 2.0 ) continuous ADT since time . Patients initiate receive ADT LHRH agonist ( without antiandrogen ) intend duration ADT least 12 month time randomization . Patients undergoing bilateral orchiectomy history procedure also eligible . For patient already ADT , therapy must continuous , one miss delay dose ( &gt; 1 mo delay ) one year period , patient eligible . Patient baseline BMD Tscore &lt; 2.0 lumbar spine ( L2L4 ) and/or total hip eligible Life expectancy least 12 month Zubrod performance status 0 , 1 , 2 Exclusion Criteria Patients receive bisphosphonate therapy past 6 month Metabolic bone disease include Paget 's disease hyperparathyroidism vitamin D deficiency . Patients vitamin D deficiency secondary hyperparathyroidism due vitamin D deficiency may treat reassessed consideration trial , detail Appendix 9 . Radiographic evidence bone metastases Patients receive treatment systemic corticosteroid within past 12 month ( short term corticosteroid therapy one month duration , e.g . acute illness like asthma exacerbation , acceptable ) Patients prior exposure anabolic steroid growth hormone within past 6 month Current treatment estrogen complementary medicine know contain estrogens Patients previous concomitant malignancy within past 5 year except adequately treat basal squamous cell carcinoma skin , colonic polyp noninvasive malignancy remove Patients nonmalignant condition would confound evaluation primary endpoint , impair tolerance therapy , prevent compliance protocol , include : uncontrolled infection uncontrolled type 2 diabetes mellitus disease influence bone metabolism , Paget 's disease uncontrolled thyroid parathyroid dysfunction cardiovascular , renal , hepatic , pulmonary neurologic/psychiatric disease would prevent prolonged followup Patients clinical radiological evidence exist fracture lumbar spine either hip Patients history lumbar spine surgery directly involve bone result implanted hardware ; render lumbar spine evaluable ( Some patient history laminectomy alone may qualify ) . Patients history unilateral fracture hip due trauma unilateral hip surgery hip lumbar spine evaluable . Patients lumbar spine least one hip evaluable reason . Patients treat systemic investigational drug ( ) /or device ( ) within past 30 day Patients prior treatment osteoporosis except calcium vitamin D Patients abnormal renal function evidence either serum creatinine great 3 mg/dL calculate creatinine clearance 40 ml/minute less ( Use CockcroftGault equation . See Appendix 5 ) . Corrected ( adjust serum albumin ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/L ) \ Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>